as common in Japanese than in Caucasians or AfricanAmericans.
When both the *ml and *m2 variant alleles were present, inducibility and enzymatic activity were increased relative to the homozygous wildtype (14) . Increased AHH activity and CYP1A1 gene inducibility in lymphocytes of individuals homozygous (14, 15) or heterozygous (14) for the *m2 variant allele have been reported. The functional significance of the *m3 and *m4 alleles has not yet been described.
The only study that examined the association between CYP1A1 polymorphism and prostate cancer risk was a hospital-based case-control study of 115 cases and 204 controls conducted in Japan (16) . The odds ratios associated with prostate cancer risk was 2.6 (95 percent confidence interval (CI): 1.11, 6.25) for individuals homozygous for the mutant *m2 allele (Val/Val) and 1.4 (95 percent CI: 0.86, 2.29) for individuals heterozygous for the *m2 allele.
CYP2C19 plays an important role in the metabolism of a number of therapeutic drugs such as 5-mephenytoin, omeprazole, diazepam, imipramine hydrochloride, and proguanil hydrochloride. So far there is no evidence to suggest its involvement in the metabolism of environmental carcinogens or endogenous compounds. Two point mutations in CYP2C19 that contribute to the S-mephenytoin poor metabolizer phenotype have been identified: a G-to-A mutation in exon 5 (CYP2C19*2) and a G-to-A mutation in exon 4 (CYP2C19*3) (17, 18) . Approximately 2-5 percent of Caucasians and 13-23 percent of Asians are poor metabolizers (19) . The *2 and *3 alleles account for 100 percent and 85 percent of the defective alleles in Asians and Caucasians, respectively. The *3 allele has only been found in Asians. A Swedish study comparing frequencies of *1 (wildtype) and *2 alleles between 178 prostate cancer cases and 160 controls found the odds ratio associated with the poor metabolizer genotype to be 1.13 (95 percent CI: 0.3, 4.27) (20) .
CYP2D6 catalyzes the metabolism of several dozen therapeutic compounds (21, 22) , including antiarrhythmics, tricyclic antidepressants, beta-blockers, and neuroleptics. It is also one of the enzymes that activates tobacco-specific nitrosamines, such as 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone (NNK) (23) . CYP2D6 activity toward probe drugs, such as debrisoquine sulfate or dextromethorphan hydrobromide, ranges from being ultrafast to completely absent and the genotype-phenotype correlation has been well studied (24, 25) . About 5-10 percent of the Caucasian population are "poor metabolizers" with two inactivation alleles. There have been three studies that examined the association of CYP2D6 genotype and the risk of prostate cancer. The Physicians' Health Study (26) determined the frequency of CYP2D6*4 allele (the *B allele), the most common genetic mutation for the poor metabolizer phenotype, among 571 cases and 767 matched controls. There was little association between the presence of the *4 allele and prostate cancer risk: the odds ratio associated with being heterozygous was 1.19 (95 percent CI: 0.94, 1.51) and that associated with being homozygous was 1.37 (95 percent CI: 0.86, 2.2). Similarly, a study of 94 cases and 160 controls of white Spanish men did not find a difference in the prevalence of variant alleles between cases and controls (27) . A third study found a modestly increased risk associated with the poor metabolizer genotypes among a Swedish but not among a Danish population (20) .
CYP3A4 is the most abundant cytochrome P450 in human liver. In addition to metabolizing approximately half of the therapeutic drugs that are in use and some tobacco carcinogens, it catalyzes 2p-(trace), 6fJ-, and 15(3-(trace) hydroxylation of testosterone, 2-and 4-hydroxylation of estradiol, and 16a hydroxylation of estrone (28, 29) . CYP3A4 is highly inducible by barbiturates, glucocorticoids, and rifampicin. It is inhibited by antifungal ketoconazole and fucocoumarins found in grapefruit. Substantial inter-individual variation in its activity has been reported; between different liver samples, there was a 31-fold variation in its activity toward testosterone (30). It is not clear whether environmental or endogenous factors are responsible for such a large difference. Rebbeck et al. (31) and Walker et al. (32) recently reported an A-»G transition in the nifedipine-specific element in the 5' regulatory region of the CYP3A4 gene, and also the frequencies for the variant G allele of 9 percent, 53 percent, and 0 percent among Caucasian-Americans, African-Americans, and Chinese in Taiwan, respectively (31, 32) . These authors hypothesized that men with the variant allele may have decreased testosterone hydroxylation, thus shunting testosterone metabolism toward the formation of the biologically more active dihydrotestosterone, which in turn stimulates the growth of the prostate and influences clinical presentation of prostate cancer (31) . Among 230 non-Hispanic Caucasian incident prostate cancer cases identified in a urologic oncology clinic, they observed that individuals carrying the G allele were more likely to have late stage disease (odds ratio (OR) = 2.1, 95 percent CI: 1.09, 4.05). Similar results were obtained in a study of 174 African-American prostate cancer patients. Men homozygous for the variant allele tend to present with higher grade and stage of disease (OR = 1.7,95 percent CI: 0.9, 3.4) (33). However, it appears that the variant allele either has no influence on the activity or amount of CYP3A4 (30, 34) , or that it actually may be associated with higher expression of CYP3A4 (35) . Clearly, additional large population-based studies will be required to confirm or refute the epidemiologic findings, and if confirmed, more studies will be required to elucidate the biologic mechanisms by which the CYP3A4 genotypes are associated with the stage and grade of prostate cancer.
Glutathione S-transferases are a multigenic family of dimeric enzymes that catalyze the conjugation of a large number of carcinogens and endogenous compounds with reduced glutathione, as well as isomerization of androst-5-ene-3,17-dione to the immediate precursor of testosterone, androst-4-ene-3,17-dione (36) . It appears that glutathion Stransferases are involved in the intracellular transport of steroid hormone (37) . Based on sequence homology, four classes of cytosolic glutathion 5-transferases have been identified in humans: alpha, mu, pi, and theta.
The mu class GSTM1 isoenzyme shows in vitro detoxification of benzo[a]pyrene-4,5-oxide and benzo[a]pyrene-7,8-diol-9,10-oxide. Large inter-individual and inter-racial differences exist in its activity toward the synthetic substrate frans-stilbene oxide (TSO). Approximately 50 percent of most Caucasian populations lack GSTMI activity due to a deletion of the GSTMI gene (38) . The association between GSTMI genotype and the risk of prostate cancer has been studied among Japanese, Danish, American, and German populations (16, (39) (40) (41) (42) , with no overall increased risk associated with the null genotype.
GSTP1 is highly efficient in conjugating glutathione with the ultimate carcinogen of benzo[a]pyrene, (+)-7p\8a-dihydroxy-9a,10 a-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene (43) . Over expression of GSTP1 is found in many tumors and is related to the tumors' resistance to chemotherapeutic agents such as cisplatin (44) . However, absence of GSTP1 expression is common in prostate cancer and prostate intraepithelial neoplasia due to hypermethylation of GSTP1 promotor (45) (46) (47) . Two genetic polymorphisms have been identified that are associated with reduced enzymatic activity and altered enzyme kinetics (48) (49) (50) (51) . The GSTP1 *b variant allele contains an A313G change, leading to a Ile-to-Val change in amino acid 105 within the active site of the enzyme; the GSTP1 *c variant allele contains an Ala-to-Val change at amino acid 114 (52, 53) . Approximately 7-15 percent of Caucasians are homozygous for the GSTP1 *b variant allele. A study of prostate cancer in a Scottish population observed a statistically imprecise 60 percent reduction in risk associated with having two GSTP1 *a alleles (54), while three other European studies did not find an association (20, 39, 42) .
The GSTT1 isozyme metabolizes ethylene oxide (55), mono-and di-halomethanes (56, 57) , and di-epoxybutane (58) . Approximately 20 percent of Caucasians, 58 percent of Chinese, 38 percent of Malays, and 16 percent of Indians lack the enzymatic activity due to a homozygous deletion of the gene (59) (60) (61) (62) . The null genotype is associated with susceptibility to sister-chromatid exchange and cytogenetic damage induced by diepoxybutane, a carcinogenic metabolite of 1,3-butadiene (63). 1,3-Butadiene is present in petrochemicals, cigarette smoke, and burned organic material. One study on prostate cancer showed a moderately increased risk associated with the non-null genotype (40, 41) , while two other studies did not (39, 42) .
Arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) catalyze the activation and/or deactivation of a wide variety of aromatic arylamines, heterocyclic amines, and hydrazine drugs (64, 65) . NAT1 and NAT2 genes are independently expressed, but have overlapping substrate specificities (66) . Both enzymes are found in the prostate epithelium (27, 67) .
Polymorphisms of Metabolic Genes 33
Both genes are polymorphic. Thus far, 24 NAT! and 26 NAT2 alleles have been identified in humans. There are large differences in the allele frequencies among different racial groups, and, thus, acetylator genotypes and phenotypes (65, (68) (69) (70) (71) (72) (73) (74) . A recent review describes the nucleotide and amino acid changes associated with the various alleles and the deduced phenotypes from genotypes. It also summarizes results of molecular epidemiologic studies assessing the association of NAT1 and NAT2 genotypes with cancer risk of the bladder, colon, breast, lung, head and neck, and prostate (75). Although some studies suggest that NAT1 and NAT2 polymorphisms may influence susceptibility to these cancers, others do not.
A study conducted in Japan has evaluated the association between NAT1 polymorphism and prostate cancer risk (101 cases and 97 controls) (76). Relative to individuals heterozygous for the * 10 allele and those with other genotypes, individuals homozygous for the *10 allele had a 2.4-fold increase in risk (95 percent CI: 1.0, 5.6). A study of Swedish (178 cases, 160 controls) and Danish subjects (153 cases, 359 controls) (20) , and a study of Spanish subjects (94 cases, 160 controls) (27) have examined the association between the NAT2 genotypes and prostate cancer risk. Neither found an association. NAD(P)H:quinone oxidoreductase (NQOl) catalyzes the two-electron reduction of hydroquinones and quinones and protects cells from potential oxidative damage (77). It reduces the mutagenicity of B[a]P quinones (78); it prevents benzene poisoning through conversion of benzoquinone to less toxic metabolites (79). It is also involved in the bioactivation of chemotherapeutic agents, such as mitomycin C (80). It is highly inducible by a variety of xenobiotics, including polynuclear aromatic hydrocarbons (77). Large inter-individual variation in enzyme activity exists; about 4 percent of the English population lack NQOl activity (81). The 609 C-¥T mutation in exon 6 of NQOl corresponding to a Prol87Ser amino acid change is associated with a loss of NQOl enzyme activity (82). NQOl activity of heterozygotes appears to be a third that of homozygous wildtypes (83). The frequency of the variant allele is 0.25, 0.43, 0.22, and 0.44 for non-Hispanic whites, Mexican Hispanics, African-Americans, and Asians, respectively (84). A single small study on prostate cancer of Germans found no difference in genotype frequencies between cases (n =54) and controls (n = 100) (85).
SUMMARY
The study of associations between genetic polymorphisms of metabolic enzymes and prostate cancer risk can provide insight into the potential etiologic role of xenobiotics in prostate cancer development. To date there is little evidence that the incidence of prostate cancer is influenced by any of the genetic polymorphisms described above. However, the number of subjects studied generally has been small, so it would be premature to conclude that the substances metabolized by enzymes encoded by these candidate genes are not of carcinogenic importance, or to conclude that the polymorphisms of these genes do not play a role in prostate cancer susceptibility. Larger-scale studies of these and other genes, such as genes that repair cellular damage and regulate cell growth, are needed. Since gene-gene and gene-environment interactions may contribute to cancer risk, it would be desirable to conduct studies in which both biomarkers (or other measures) of exposure and polymorphisms of multiple genes are examined.
